Pratz, K. Et Al. 2021. Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine.. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15_suppl , 7018.

Pratz, K., Jonas, B. A., Pullarkat, V., Recher, C., Schuh, A. C., Thirman, M. J., ... Garcia, J. S.(2021). Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine.. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15_suppl, 7018.

Pratz, Keith Et Al. "Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine.," JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15_suppl, 7018, 2021

Pratz, Keith Et Al. "Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine.." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15_suppl, pp.7018, 2021

Pratz, K. Et Al. (2021) . "Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine.." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15_suppl, p.7018.

@article{article, author={Keith Pratz Et Al. }, title={Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2021, pages={7018} }